ESTUDIO DE EXTENSIÓN ABIERTO CON UN ÚNICO BRAZO DE TRATAMIENTO DEL ESTUDIO MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO, CON GRUPOS PARALELOS PARA COMPARAR LA EFICACIA Y SEGURIDAD DE 0,5 MG FTY720 ADMINISTRADO POR VÍA ORAL UNA VEZ AL D ÍA VERSUS PLACEBO EN PACIENTES CON ESCLEROSIS MÚLTIPLE PRIMARIA PROGRESIVA.

Meeting Abstract. 2021

Anti-lipid oligoclonal IgM bands contribute to progressive multifocal leukoencephalopathy (PML) risk stratification in multiple sclerosis patients treated with natalizumab

Villar, L.; (...); Alvarez-Cermeno, J. C.

Article. 2013

Antimicrobial stewardship programme implementation in a medical ward

Ruiz, J; (...); Poveda, JL

Article. 2018

Antimicrobial stewardship programme in critical care medicine: A prospective interventional study

Ruiz, J; (...); Catellanos, A

Article. 10.1016/j.medin.2017.07.002. 2018

Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).

Pereyra-Rodríguez JJ; (...); Ortiz de Frutos FJ

Letter. 10.1111/jdv.19432. 2023

Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer's Disease and Frontotemporal Dementia.

Álvarez-Sánchez L; (...); Cháfer-Pericás C

Article. 10.3390/ijms24021226. 2023

Assessment of the quality of sample labelling for clinical research.

Pérez-Huertas P; (...); Poveda-Andrés JL

Article. 10.7399/fh.2016.40.2.9753. 2016

Assessment of the reproducibility of oligoclonal IgM band detection for its application in daily clinical practice

Espiño M; (...); Villar LM

Article. 10.1016/j.cca.2014.08.004. 2015

Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis.

Lunemann JD; (...); Comabella M

Article. 10.1212/NXI.0000000000200270. 2024

Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs.

Monreal, Enric; (...); Villar LM

Article. 10.1001/jamaneurol.2023.0010. 2023

Association of SNPs with the efficacy and safety of immunosuppressant therapy after heart transplantation

Sánchez-Lázaro I; (...); Aliño SF

Article. 10.2217/pgs.15.39. 2015

Atypical periodic alternating nystagmus responding to high-dose intravenous immunoglobulins: a case report

Argente-Escrig, H; (...); Casanova Estruch B

Article. 10.1186/s12974-017-0846-1. 2017

Autologous hematopoietic stem cell transplantation for pediatric multiple sclerosis: a registry-based study of the Autoimmune Diseases Working Party (ADWP) and Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Burman, J; (...); Farge, D

Article. 10.1038/bmt.2017.40. 2017

Autologous hematopoietic stem cell transplantation in multiple sclerosis: updating outcomes in the Valencian cohort.

Boix Lago, A.; (...); Casanova Estruch, B.

Meeting Abstract. 2023

Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis

Casanova, B; (...); Coret, F

Article. 10.1007/s10072-017-2933-6. 2017

Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.

Iglesias Gómez R; (...); Poveda Andrés JL

Article. 10.1136/ejhpharm-2021-002741. 2021

Basal levels of serum neurofilament light in normal aging and multiple sclerosis patients

Gasque Rubio, R.; (...); Casanova Estruch, B.

Meeting Abstract. 2021

Bayesian pharmacokinetic individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A

Megias-Vericat, JE; (...); Bonanad, S

Meeting Abstract. 2018

Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A

Poveda-Andrés JL, Bosó-Ribelles V

Article. 10.1016/j.thromres.2018.12.027. 2019

Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.

Fernandez Rivera C; (...); Hernandez D

Article. 10.1111/ctr.14550. 2022

Bioenergetic Failure in Rat Oligodendrocyte Progenitor Cells Treated with Cerebrospinal Fluid Derived from Multiple Sclerosis Patients

Mathur, D; (...); Lopez-Rodas, G

Article. 10.3389/fncel.2017.00209. 2017

Biomarkers in multiple sclerosis: an update for 2014

Fernandez O; (...); Montalban X

Review. 10.33588/rn.5812.2014247. 2014

Biosimilares: viejas polemicas con nuevos argumentos.

Editorial Material. 10.7399/fh.2015.39.3.8978. 2015

BK Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation in the Pediatric Population

Perez-Huertas, P; (...); Poveda-Andres, JL

Article. 10.1177/1043454216631952. 2017

Brain atrophy in relapsing optic neuritis is associated to anti-mog antibodies

Navarro Canto, L.; (...); Casanova Estruch, B.

Meeting Abstract. 2019

Brain Atrophy in Relapsing Optic Neuritis Is Associated With Crion Phenotype

Canto, LN; (...); Estruch, BC

Article. 10.3389/fneur.2019.01157. 2019

Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis.

Perez-Miralles, Francisco Carlos; (...); Casanova, Bonaventura

Article. 10.1002/brb3.2044. 2021

Breakthrough invasive fungal disease in high-risk hematologic malignancies in children: a single-center experience

Garcia-Robles, AA; (...); Fernandez-Navarro, JM

Meeting Abstract. 2017

Bypassing hazard of housekeeping genes: their evaluation in rat granule neurons treated with cerebrospinal fluid of multiple sclerosis subjects

Mathur D; (...); Burgal-Marti M

Article. 10.3389/fncel.2015.00375. 2015

Calidad y Legibilidad de la Hoja de Informacion al Paciente en Estudios con Analisis Farmacogenetico.

Ruiz Ramos J; (...); Poveda Andrés JL

Article. 2015

Case Report: Exacerbation of Relapses Following mRNA COVID-19 Vaccination in Multiple Sclerosis: A Case Series.

Quintanilla-Bordás C; (...); Casanova B

Article. 10.3389/fneur.2022.897275. 2022

Cerebrospinal fluid kappa free light chains and IgM index for diagnosis and prognosis in multiple sclerosis

Gil-Perotin, S.; (...); Casanova, B.

Meeting Abstract. 2021

Cervical spinal cord T2 lesions independently predict early conversion to secondary progressive multiple sclerosis: a longitudinal 10-year study

Lacruz-Ballester, L.; (...); Casanova-Estruch, B.

Meeting Abstract. 2021

Circulating mirna signatures in PPMS

Martin, MMS; (...); Torrenta, LRI

Meeting Abstract. 2020

Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients

Article. 10.1016/j.thromres.2021.07.009. 2021

Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study

Oreja-Guevara, Celia; (...); Rio, Jordi

Article. 10.1016/j.msard.2024.105787. 2024

Clinical evaluation of rituximab treatment for neuromyelitis optica

Fernández-Megía MJ; (...); Poveda-Andrés JL

Article. 10.1016/j.nrl.2014.09.001. 2015

Clinical experience with rituximab in the treatment of refractory multiple sclerosis

Gascon, F.; (...); Coret, F.

Meeting Abstract. 2014

Clinical experiences with cannabinoids in spasticity management in multiple sclerosis

Lorente Fernández L; (...); Casanova-Estruch B

Article. 10.1016/j.nrl.2013.06.014. 2014

Clinical impact of early brain atrophy in clinically isolated syndromes.

Pérez-Miralles F; (...); Montalban X

Article. 10.1177/1352458513488231. 2013

Clinical pharmacy services: from cost-effectiveness analysis to a productivity indicators model

Nogueras, A; (...); Calleja, MA

Letter. 10.1136/ejhpharm-2019-001905. 2019

Clinical trajectories of patients with multiple sclerosis from onset and their relationship with serum neurofilament light chain levels

Quintanilla-Bordas, Carlos; (...); Casanova, Bonaventura

Article. 10.3389/fneur.2024.1477335. 2024

Clinical, demographic and laboratory data associated with PML risk in patients treated with natalizumab

Toboso, I; (...); Villar, LM

Meeting Abstract. 2017

Cognitive impairment in multiple sclerosis: diagnosis and monitoring.

Meca-Lallana, Virginia; (...); Perez-Miralles, Francisco

Article. 10.1007/s10072-021-05165-7. 2021

Cognitive performance and health-related quality of life in patients with neuromyelitis optica spectrum disorder

Lopez-Soley, Elisabet; (...); Solana, Elisabeth

Meeting Abstract. 2022

Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder.

Lopez-Soley E; (...); Solana E

Article. 10.3390/jpm12050743. 2022

Collaborative model of home delivery program in haemophilia through an association of patients

Megias-Vericat, JE; (...); Bonanad, S

Meeting Abstract. 2018

Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis.

Gil-Perotin S; (...); Casanova B

Article. 10.3389/fneur.2019.01008. 2019

Comorbilidad en esclerosis multiple y su abordaje asistencial.

Estruch BC

Abstract of Published Item. 10.1016/S0025-7753(15)30004-X. 2014

Comparative Assessment of Simoa and Lumipulse for Measuring Serum Neurofilament Light Chain in Multiple Sclerosis Patients

Gasque-Rubio, Raquel; (...); Perez-Miralles, Francisco

Article. 10.1155/2024/1950913. 2024

Comparison of pharmacokinetic estimates using generic and specific population pharmacokinetic models of plasma-derived factor VIII/VWF using WAPPS-Hemo

Meeting Abstract. 2020

Consensus document on spasticity in patients with multiple sclerosis

Oreja-Guevara, Celia; (...); Fernandez, Oscar

Article. 10.33588/rn.5708.2013374. 2013

Consensus document on the multidisciplinary management of neurogenic lower urinary tract dysfunction in patients with multiple sclerosis.

Medina-Polo J; (...); López-Fando L

Article. 10.1002/nau.24276. 2020

Consensus guidelines for the timely detection and diagnosis of disease progression in multiple sclerosis patients

Oreja-Guevara, C; (...); Meca-Lallana, J

Meeting Abstract. 2020

Consensus on early detection of disease progression in patients with multiple sclerosis

Meca-Lallana, Jose E.; (...); Oreja-Guevara, Celia

Article. 10.3389/fneur.2022.931014. 2022

Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano JB; (...); Soto-Ortega I

Article. 10.1016/j.farma.2023.01.003. 2023

Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada

Article. 10.1016/j.farma.2023.04.002. 2023

COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA

Gironella, M.; (...); Oyaguez, I

Meeting Abstract. 2019

COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN

Sanchez-Alvarez, Emilio E.; (...); Hernaez Colque, M.

Meeting Abstract. 2024

Cost-effectiveness analysis of implementing an antimicrobial stewardship program in critical care units

Ruiz-Ramos, J; (...); Ramirez, P

Article. 10.1080/13696998.2017.1311903. 2017

Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.

Poveda JL; (...); Torres C

Article. 10.1080/14737167.2019.1635014. 2020

COST-EFFECTIVENESS OF CLADRIBINE TABLETS AND FINGOLIMOD IN THE TREATMENT OF REMITTING MULTIPLE SCLEROSIS WITH HIGH DISEASE ACTIVITY IN SPAIN

Trillo, JL; (...); Torres, C

Meeting Abstract. 10.1016/j.jval.2018.09.2029. 2018

Cost-effectiveness of methoxy polyethylene glycolepoetin beta versus conventional epoetin in the treatment of anaemia secondary to chronic kidney disease in clinical practice

Lorente-Fernandez, L; (...); Poveda-Andres, JL

Article. 10.1136/ejhpharm-2013-000426. 2015

COSTS OF THE MANAGEMENT OF HEMOPHILIA A WITH INHIBITORS IN SPAIN

Bonanad, S; (...); Gonzalez-Dominguez, A

Meeting Abstract. 2020

Costs of the management of hemophilia A with inhibitors in Spain

Bonanad, S; (...); Gonzalez-Dominguez, A

Article. 10.33393/grhta.2021.2234. 2021

Cross-reactivity of a pathogenic autoantibody to a tumor antigen in GABA A receptor encephalitis.

Brändle SM; (...); Dornmair K

Article. 10.1073/pnas.1916337118. 2021

Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate (R)) and BAY 81-8973 (KovaltryA (R)) in patients with severe or moderate haemophilia A in prophylaxis

Letter. 10.1111/hae.13733. 2019

Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products

Eduardo Megias, Juan; (...); Iorio, Alfonso

Meeting Abstract. 10.1182/blood-2019-127946. 2019

CSF chitinase 3-like-1 association with disability of primary progressive MS

Article. 10.1212/NXI.0000000000000815. 2020

Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.

Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL

Editorial Material. 10.1016/j.farma.2024.08.001. 2024

Cytokines profile in the cerebrospinal fluid in chronic relapsing inflammatory demyelinating diseases of the central nervous system

Simo-Castello, M.; (...); Coret, F.

Meeting Abstract. 2014

Changes in Brain Volume in Specific Regions could be related to Disability Progression in Primary Progressive Multiple Sclerosis Patients

Miralles, FP; (...); Casanova, B

Meeting Abstract. 2019

Changes in brain volume in specific regions could predict worsening cognition in primary progressive multiple sclerosis

Meeting Abstract. 2019

Characterization of individual IgM oligoclonal band antibodies from the cerebrospinal fluid (CSF) of multiple sclerosis patients to identify their antigens

Beltran, E.; (...); Dornmair, K.

Article. 2013

Characterization of the gait in patients with relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis measured by FeetMe (R) integrated sensor insole system: Results of the interim analysis

Izquierdo Ayuso, G.; (...); Casanova Estruch, B.

Meeting Abstract. 2021

Chitinase-3-like protein 1 could be a predictor of disability progression in patients with primary progressive multiple sclerosis

Meeting Abstract. 2018

Chitinase-3-like protein 1 could be a predictor of disability progression in patients with primary progressive multiple sclerosis: A one-year follow-up

Meeting Abstract. 2019

Chronic hyperammonemia induces peripheral inflammation that leads to cognitive impairment in rats: reversal by anti-tnfa treatment.

Balzano T; (...); Felipo V

Article. 10.1016/j.jhep.2019.01.008. 2020

Daclizumab in multiple sclerosis.

Perez-Miralles, FC

Review. 10.33588/rn.6608.2018083. 2018

Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review

Megias-Vericat, JE; (...); Montesinos, P

Review. 10.1080/17512433.2019.1573668. 2019

Deciphering Multiple Sclerosis Progression.

Meca-Lallana, Virginia; (...); Perez-Miralles, Francisco Carlos

Review. 10.3389/fneur.2021.608491. 2021

Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project

Blade, J; (...); Lizan, L

Article. 10.1136/bmjopen-2017-018850. 2018

Description of the Characteristics of Multiple Sclerosis Patients in the Region of Valencia (Spain) Who Requested Treatment with Disease-Modifying Drugs during the 2005-2014 Decade

Ribes García S; (...); Casanova Estruch B

Article. 10.1159/000446580. 2016

Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.

Salinas P; (...); Escaned J

Article. 10.1016/j.carrev.2021.11.015. 2021

Design and Validation of an Expanded Disability Status Scale Model in Multiple Sclerosis.

Barreiro-Gonzalez, Antonio; (...); Casanova, Bonaventura

Article. 10.1159/000519772. 2022

Determining the value contribution of emicizumab (Hemlibra (R)) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis

Alvarez-Roman, MT; (...); Badia, X

Article. 10.1177/2284240319880534. 2019

DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

Alvarez, E.; (...); Badia, F. J.

Meeting Abstract. 2019

Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.

Abad, Maria Reyes; (...); Gil, Alicia

Article. 10.33393/grhta.2024.3041. 2024

Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis

Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther

Article. 10.1002/jvc2.275. 2024

DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN

Poveda, J. L.; (...); Vitoria, I

Meeting Abstract. 2019

Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain

Badia, X; (...); Poved, JL

Article. 10.1080/21678707.2019.1652163. 2019

Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients

Casanova, B; (...); Coret, F

Article. 10.1007/s10072-018-3442-y. 2018

DISCOVER STUDY, FIRST ANALYSIS SPECIFIC FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS BURDEN AND COST IN SPAIN: INTERIM ANALYSIS RESULTS

Oreja-Guevara, C; (...); Meca-Lallana, J

Meeting Abstract. 2020

Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology.

Brieva, Luis; (...); Moral, Ester

Article. 10.1016/j.msard.2022.103805. 2022

Disturbed Glucose Metabolism in Rat Neurons Exposed to Cerebrospinal Fluid Obtained from Multiple Sclerosis Subjects

Mathur, D; (...); Burgal-Marti, M

Article. 10.3390/brainsci8010001. 2018

Documento de consenso sobre la espasticidad en pacientes con esclerosis multiple.

Oreja-Guevara C; (...); Fernández Ó

Abstract of Published Item. 10.33588/rn.5708.2013374. 2013

Does benign multiple sclerosis exist?

Verdini Martinez, Laura; (...); Casanova, Bonaventura

Meeting Abstract. 2023

Dose banding aplicado a la elaboracion de antineoplasicos: una revision narrativa de la literatura.

Pérez Huertas P; (...); Poveda Andrés JL

Article. 10.7399/fh.2015.39.4.8839. 2015

Drug Interaction Between Oral Cyclosporine Modified and Iron

Domingo-Chiva, E; (...); Poveda-Andres, JL

Article. 10.1177/1060028013514734. 2014

Dynamic 18F-FDG PET to detect differences among patients with progressive and relapsing multiple sclerosis: a pilot study

Quintanilla Bordas, Carlos; (...); Casanova, Bonaventura

Meeting Abstract. 2023

Dyschromatopsia in multiple sclerosis reflects diffuse chronic neurodegeneration beyond anatomical landmarks.

Barreiro-González A; (...); Casanova B

Article. 10.1007/s13760-020-01516-x. 2020

Early Alzheimer's Disease Screening Approach Using Plasma Biomarkers

Alvarez-Sanchez, Lourdes; (...); Chafer-Pericas, Consuelo

Article. 10.3390/ijms241814151. 2023

Early beginning of alemtuzumab: Changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study.

Meca-Lallana, J E; (...); Calles Hernandez, C

Article. 10.1016/j.nrleng.2021.06.006. 2023

Early beginning of alemtuzumab: changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study

Meca-Lallana, J. E.; (...); Hernandez, C. Calles

Article. 10.1016/j.nrl.2021.06.007. 2024

Early experience with compassionate use of 2 hydroxypropyl-beta-cyclodextrin for Niemann-Pick type C disease: review of initial published cases

Review. 10.1007/s10072-017-2833-9. 2017

Economic impact and clinical profile of the secondary progressive multiple sclerosis (SPMS) patient: the DISCOVER study

Oreja-Guevara, C.; (...); Meca-Lallana, J. E.

Meeting Abstract. 2021

ECONOMIC IMPACT LINKED TO THE REDUCTION OF EXACERBATIONS WHEN A TREATMENT REGIME WITH INHALED ANTIBIOTICS IS SWITCHED TO AZTREONAM LYSINE IN PATIENTS WITH CYSTIC FIBROSIS AND CHRONIC PULMONARY INFECTION CAUSED BY PSEUDOMONAS AERUGINOSA

Sole A; (...); Casado MA

Meeting Abstract. 10.1016/j.jval.2014.08.1659. 2014

Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan

Ribera, E; (...); Hernandez-Novoa, B

Article. 10.1016/j.eimc.2016.11.015. 2018

Economic impact of the secondary progressive multiple sclerosis in spain: interim analysis of the discover study

Oreja-Guevara, C; (...); Meca-Lallana, J

Meeting Abstract. 2020

Eculizumab for a catastrophic relapse in NMOSD: case report.

Gorriz, David; (...); Casanova, Bonaventura

Article. 10.1007/s10072-023-06971-x. 2023

Efecto de la adición de fortificantes y de módulo de proteínas en la osmolalidad de la leche materna donada.

Torres Martínez E; (...); Vento M

Article. 10.1016/j.anpedi.2020.03.009. 2020

EFFECT OF CYP3A5 GENOTYPE ON TACROLIMUS DOSE REQUIREMENT, NEPHROTOXICITY AND ACUTE REJECTION IN KIDNEY TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES

Rojas, L.; (...); Alino, S. F.

Article. 2013

Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies

Rojas L; (...); Aliño SF

Article. 10.1038/tpj.2014.38. 2015

Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.

Meca-Lallana JE; (...); Llarena C

Article. 10.1007/s40120-023-00557-7. 2023

Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment

Palanques-Pastor T; (...); Poveda Andrés JL

Article. 10.1159/000517813. 2021

Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.

Alcala, Carmen; (...); Casanova, Bonaventura

Article. 10.1007/s00415-022-10989-0. 2022

Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial.

Villoslada P; (...); NeuroAdvan study

Article. 10.1212/NXI.0000000000000147. 2015

EFFECTS OF POLYMORPHIMS OF CYP3A5 AND ABCB1 GENES ON CHRONIC NEPHROPATHY: COHORT STUDY

Rojas, L.; (...); Alino, S. F.

Article. 2013

Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study

Alcala, C; (...); Casanova, B

Article. 10.1007/s00415-018-8899-3. 2018

eLearning of pharmacokinetic monitoring in hemophilia with application in the clinical practice

Bonanad, S; (...); Megias-Vericat, JE

Meeting Abstract. 2018

Elevation of Chi3l1 in acute disseminated encephalomyelitis: implications in pathogenesis

Gil-Perotin, S; (...); Casanova-Estruch, B

Meeting Abstract. 2018

Elevation of serum neurofilament light-chain levels disclose possible occult progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient receiving ozanimod: a case report.

Quintanilla-Bordás C; (...); Pérez-Miralles FC

Case Reports. 10.3389/fimmu.2024.1465678. 2024

Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABA(A) receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies

Petit-Pedrol M; (...); Dalmau J

Article. 10.1016/S1474-4422(13)70299-0. 2014

Escalation vs. Early Intense Therapy in Multiple Sclerosis.

Casanova, Bonaventura, Quintanilla-Bordas, Carlos, Gascon, Francisco

Article. 10.3390/jpm12010119. 2022

Estudio de utilizacion de boceprevir y telaprevir para el tratamiento de la hepatitis C cronica.

Marrero-Álvarez P; (...); Poveda-Andrés JL

Abstract of Published Item. 10.7399/FH.2014.38.1.1128. 2014

EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING & REIMBURSEMENT (P&R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN

Badia, F. J.; (...); Shepherd, J.

Meeting Abstract. 2019

Evaluating the complement C1q levels in serum and cerebrospinal fluid in multiple sclerosis patients: Could it serve as a valuable marker in clinical practice?

Tortosa-Carreres J; (...); Pérez-Miralles FC

Article. 10.1016/j.jneuroim.2024.578428. 2024

Experience in the management of immunosuppressant treatment with hepatitis C virus protease inhibitors

Ruiz Ramos J; (...); Poveda Andrés JL

Article. 10.1016/j.gastrohep.2014.05.004. 2014

Experience of Home Delivery Program in Haemophilia Through an Association of Patients

Megias Vericat, J. E.; (...); Bonanad Boix, S.

Meeting Abstract. 2017

EXPERTS CONSENSUS ON THE FUTURE OF RARE DISEASES CARE AND ORPHAN DRUGS ACCESS IN SPAIN: A DELPHI STUDY

Paz S; (...); Urcelay J

Meeting Abstract. 10.1016/j.jval.2015.09.2016. 2015

Exploratory analysis for the implementation of antineoplastic logarithmic dose banding

Albert-Mari, A; (...); Poveda-Andres, JL

Article. 10.1007/s11096-018-0714-9. 2018

EXTENDED MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD EXTENSION STUDY

F, de Andres-Nogales; (...); Martinez, M.

Meeting Abstract. 2019

Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease

Beltran, B; (...); Nos, P

Article. 10.1159/000492626. 2019

Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report

Fernandez-Sanchez, M; (...); Poveda-Andres, JL

Article. 10.1002/bdr2.1942. 2021

Fingolimod plus steroids prevents return to clinical activity after natalizumab withdrawal

Article. 2013

Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.

Plaza J; (...); Moret-Tatay I

Article. 10.3390/ijms25073717. 2024

Genotype and Allele Frequencies of Drug-Metabolizing Enzymes and Drug Transporter Genes Affecting Immunosuppressants in the Spanish White Population

Bosó V; (...); Aliño SF

Article. 10.1097/FTD.0b013e3182a94e65. 2014

Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis

Poveda Andres, Jose Luis

Editorial Material. 2022

Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report

Company-Albir, MJ; (...); Poveda, JL

Article. 10.1111/jcpt.12568. 2017

Hazardous drugs levels in compounding area surfaces of Hospital Pharmacies Services: multicentric study

Valero-Garcia, S; (...); Spanish Hosp Pharmacy Units

Article. 10.7399/fh.10935. 2018

Hazardous drugs: new challenges, new opportunities.

Valero García S; (...); Poveda Andrés JL

Article. 10.7399/fh.2016.40.2.10462. 2016

Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study

Solana-Altabella, Antonio; (...); Martinez-Cuadron, David

Article. 10.3390/cancers14081921. 2022

High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.

El-Qutob D; (...); Carrera-Hueso FJ

Article. 10.1016/j.hrtlng.2022.02.003. 2022

High Levels of Cerebrospinal Fluid Kappa Free Light Chains Relate to IgM Intrathecal Synthesis and Might Have Prognostic Implications in Relapsing Multiple Sclerosis.

Castillo-Villalba, Jessica; (...); Casanova, Bonaventura

Article. 10.3389/fimmu.2022.827738. 2022

Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies

Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo

Article. 10.7399/fh.11729. 2022

Hospitalization budget impact during the COVID-19 pandemic in Spain.

Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.

Article. 10.1186/s13561-021-00340-0. 2021

How can artificial intelligence optimize value-based contracting?

Poveda, Jose Luis; (...); Medrano, Ignacio H.

Letter. 10.1186/s40545-022-00475-3. 2022

Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial

Zubizarreta, I; (...); Villoslada, P

Article. 10.1073/pnas.1820039116. 2019

Immune tolerance in patients with Multiple Sclerosis and Neuromyelitis Optica by peptide-loaded tolerogenic dendritic cells: final results of the phase 1b clinical trial and extension

Zubizarreta, I; (...); Villoslada, P

Meeting Abstract. 2019

Immunoglobulin M Oligoclonal Bands: Biomarker of Targetable Inflammation in Primary Progressive Multiple Sclerosis

Villar LM; (...); Bar-Or A

Article. 10.1002/ana.24190. 2014

Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1080/10428194.2016.1231405. 2017

Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart (R) in patients with multiple sclerosis

Edo Solsona MD; (...); Poveda Andrés JL

Article. 10.2147/PPA.S127508. 2017

IMPACT OF ADHERENCE ON SUBCUTANEOUS INTERFERON BETA-1A EFFECTIVENESS ADMINISTERED BY REBISMART (R) IN PATIENTS WITH MULTIPLE SCLEROSIS

Edo-Solsona, M.; (...); Poveda-Andres, J.

Meeting Abstract. 10.1016/j.jval.2016.09.512. 2016

Impact of an antimicrobial stewardship program on critical haematological patients.

Ruiz-Ramos, J; (...); Ramirez, P

Article. 10.7399/fh.2017.41.4.10709. 2017

Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.

Megías-Vericat JE; (...); Montesinos P

Article. 10.1080/10428194.2020.1839650. 2020

Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1038/tpj.2017.19. 2018

Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients' Perspective: An Observational Cross-Sectional Study

Meca-Lallana, Jose E.; (...); Maurino, Jorge

Article. 10.1007/s40120-022-00356-6. 2022

Impact of neuromyelitis optica spectrum disorder on quality of life: Assessing the patients' perspective

Meca-Lallana, Jose; (...); Maurino, Jorge

Meeting Abstract. 10.1016/j.jns.2021.118844. 2021

Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1097/FPC.0000000000000286. 2017

Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation

Ruiz J; (...); Aliño SF

Article. 10.3390/ijms160920168. 2015

Impact of stigma in patients with primary progressive multiple sclerosis: a one-year follow-up

Meeting Abstract. 2019

Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019

Badia X; (...); Hernández C

Article. 10.1186/s13023-020-01507-4. 2020

Impact of Transporter Genes Polymorphisms in Standard Induction of Acute Myeloid Leukemia

Meeting Abstract. 2015

Impact of voriconazole plasma concentrations on treatment response in critically ill patients

Ruiz, J; (...); Ramirez, P

Article. 10.1111/jcpt.12817. 2019

Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases

Edo-Solsona, MD, Vitoria-Minana, I, Poveda-Andres, JL

Article. 10.7399/fh.11262. 2020

Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients

Ruiz-Ramos, J; (...); Ramirez, P

Article. 10.1159/000478969. 2018

Improvements in Quality of Life of Patients with Multiple Sclerosis receiving Alemtuzumab in Clinical Practice: LEMVIDA study

Meca Lallana, Jose; (...); Forner, Mireia

Meeting Abstract. 10.1212/WNL.0000000000202381. 2023

Improvements in quality of life of patients with multiple sclerosis receiving alemtuzumab in clinical practice: the LEMVIDA study.

Meca-Lallana, Jose Eustasio; (...); Toledo, Baldo

Article. 10.1186/s41687-024-00822-9. 2024

Improving the efficiency of free kappa light chains as diagnostic biomarker of Multiple Sclerosis by using a novel algorithm.

Tortosa-Carreres J; (...); Pérez-Miralles FC

Article. 10.1016/j.msard.2023.104997. 2023

In Situ RT-PCR Optimized For Electron Microscopy Allows Description Of Subcellular Morphology Of Target mRNA-Expressing Cells In the Brain

LAURA CUBAS NÚÑEZ; (...); Gil-Perotin S

Article. 2017

In situ RT-PCR Optimized for Electron Microscopy Allows Description of Subcellular Morphology of Target mRNA-Expressing Cells in the Brain

Cubas-Nunez, L; (...); Gil-Perotin, S

Article. 10.3389/fncel.2017.00141. 2017

Incompatibility of undiluted busulfan injection with a needle-free valve

Cueto-Sola, M; (...); Poveda-Andres, JL

Letter. 10.2146/ajhp140111. 2014

Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis

Comabella, Manuel; (...); Luenemann, Jan D.

Article. 10.1007/s00415-024-12763-w. 2025

Individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A

Vericat, JEM; (...); Bonanad, S

Meeting Abstract. 2018

Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables

Megias-Vericat, Juan Eduardo; (...); Bonanad, Santiago

Meeting Abstract. 10.1182/blood.V128.22.3802.3802. 2016

Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: A systematic review and meta-analysis of observational studies

Megías-Vericat JE; (...); Aliño SF

Review. 10.1038/tpj.2014.80. 2015

Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy

Bastida, G; (...); Nos, P

Meeting Abstract. 10.1093/ecco-jcc/jjy222.581. 2019

Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1080/10428194.2017.1323267. 2017

Influence of pharmacokinetic/pharmacodynamic ratio on vancomycin treatment response in paediatric patients with Staphylococcus aureus bacteremia.

Ruiz J; (...); Poveda JL

Article. 10.23736/S0026-4946.18.04978-2. 2018

Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.

Megías-Vericat JE; (...); Montesinos P

Article. 10.1097/FPC.0000000000000431. 2021

Influence of Single Nucleotide Polymorphisms in Anthracycline Metabolism Pathway in Standard Induction of Acute Myeloid Leukemia

Meeting Abstract. 2015

Interdisciplinary recommendations document to improve adherence in patients with chronic inflammatory diseases: Adhing recommendations.

Bermejo San José F; (...); Sanromán-Álvarez L

Article. 10.7399/fh.2016.40.5.10180. 2016

Intraperitoneal vancomycin in neonates during peritoneal dialysis: A case report

Company-Albir, MJ; (...); Poveda, JL

Article. 10.1111/jcpt.12842. 2019

Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation

Beltrán E; (...); Dornmair K

Article. 10.1093/brain/awu205. 2014

Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol.

Solana-Altabella A; (...); Poveda JL

Article. 10.1177/1078155220904410. 2020

Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19

Palanques-Pastor, T, Lopez-Briz, E, Andres, JLP

Article. 10.1136/ejhpharm-2020-002322. 2020

Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.

Pozo-Rosich P; (...); Irimia P

Article. 10.1186/s10194-024-01747-w. 2024

Is it cost-effective to request IgM oligoclonal bands against lipids in daily practice as a biomarker for poor prognosis in multiple sclerosis?

Ribes Garcia, Sara; (...); Bonaventura, Casanova Estruch

Article. 10.1016/j.msard.2023.105033. 2023

Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.

Martin-Cerezuela, Maria; (...); Ramirez Galleymore, Paula

Article. 10.3390/antibiotics13080706. 2024

Leptomeningeal gadolinium enhancement in multiple sclerosis

Gascon-Gimenez, F; (...); Casanova, V

Meeting Abstract. 2019

Leptomeningeal gadolinium enhancement lesions in multiple sclerosis are not related to different brain volume measures

Garcia, F; (...); Casanova, B

Meeting Abstract. 2018

Lipid-specific IgM oligoclonal bands in clinically isolated syndrome: 5-years follow-up

Molla, B.; (...); Casanova, B.

Meeting Abstract. 2014

Lipid-Specific Immunoglobulin M Bands in Cerebrospinal Fluid Are Associated with a Reduced Risk of Developing Progressive Multifocal Leukoencephalopathy during Treatment with Natalizumab

Villar LM; (...); Álvarez-Cermeño JC

Article. 10.1002/ana.24345. 2015

Lipid-specific oligoclonal IgM bands: is there any influence on the response to treatment with fingolimod?

Perez-Romero, L.; (...); Casanova, B.

Meeting Abstract. 2014

Longitudinally extensive transverse myelitis with AQP4 antibodies revealing ovarian teratoma.

Frasquet M; (...); Casanova B

Article. 10.1016/j.jneuroim.2013.07.003. 2013

Long-term efficacy of alemtuzumab in multiple sclerosis: a real word multicenter Spanish experience

Rubio Alcantud, Almudena; (...); Casanova, Bonaventura

Meeting Abstract. 2023

Long-term treatment effect over disability progression in patients with relapsing multiple sclerosis

Estruch, BC; (...); Coret, F

Meeting Abstract. 2017

Magnetic resonance imaging and optical coherence tomography correlations in multiple sclerosis beyond anatomical landmarks.

Barreiro-González A; (...); Casanova B

Article. 10.1016/j.jns.2020.117180. 2020

Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.

Megías-Vericat JE; (...); Poveda-Andrés JL

Article. 2021

Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.

Vázquez Polo A; (...); Vázquez Costa JF

Article. 10.20960/nh.03946. 2022

Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A

Bonanad, S; (...); Santos, S

Article. 10.1007/s12325-021-01853-0. 2021

Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver transplantation.

Rojas LE; (...); Aliño SF

Article. 10.1097/FPC.0b013e3283642fb3. 2013

Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.

Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor

Article. 10.3390/cancers14030596. 2022

Metyrapone as treatment in the neonatal McCune-Albright syndrome

de Mingo, Carmen; (...); Garcia-Robles, Ana

Article. 10.1515/jpem-2020-0036. 2020

Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview

Garcia-Foncillas, J; (...); Gomez, MVP

Review. 10.1007/s40291-021-00544-4. 2021

miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis.

Munoz-San Martin, Maria; (...); Ramio-Torrenta, Lluis

Article. 10.1212/NXI.0000000000200069. 2023

Monitoring coagulation factors during surgery. A systematic review

Eduardo Megias-Vericat, Juan; (...); Luis Poveda-Andres, Jose

Review. 10.7399/fh.11766. 2021

Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH).

Valero-García S; (...); Delgado-Sánchez O

Article. 10.7399/fh.11655. 2021

Monitoring the quality of the hospital pharmacoterapeutic process by sentinel patient program.

Fernandez-Megia, MJ; (...); Poveda Andrés JL

Article. 10.7399/fh.10793. 2018

Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments

Gomez-Cebrian, N; (...); Pineda-Lucena, A

Review. 10.3390/cancers13184544. 2021

Multiple sclerosis patient-derived CSF induces transcriptional changes in proliferating oligodendrocyte progenitors

Haines JD; (...); Lopez-Rodas G

Article. 10.1177/1352458515573094. 2015

N. VICTOR JIMENEZ TORRES (1942-2015) IN MEMORIAM

Climente Martí M, Poveda Andrés JL, Culebras J

Biographical-Item. 10.3305/nh.2015.32.4.9704. 2015

National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)

Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel

Correction. 10.7399/fh.11740. 2021

National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies

Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis

Meeting Abstract. 10.1182/blood-2022-169938. 2022

Neuromyelitis optica associated with the use of Atezolizumab in a patient with advanced lung adenocarcinoma.

Pedrero Prieto, Manuel; (...); Casanova Estruch, Bonaventura

Article. 10.1007/s10072-023-07252-3. 2023

Neuromyelitis optica spectrum disorders Comparison according to the phenotype and serostatus

Sepúlveda M; (...); Saiz A

Article. 10.1212/NXI.0000000000000225. 2016

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab.

Toboso I; (...); Villar LM

Article. 10.3389/fneur.2020.579438. 2020

New challenges of advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2023.11.008. 2024

NFL during acute spinal cord lesions in MS: a hurdle for the detection of inflammatory activity.

Article. 10.1007/s00415-021-10926-7. 2022

Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus

Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis

Article. 10.1097/MD.0000000000032208. 2022

ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.

Poveda JL; (...); Badia X

Article. 10.1186/s13023-022-02610-4. 2023

Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosis.

Alcala Vicente, Carmen; (...); Casanova, Bonaventura

Article. 10.3389/fneur.2022.991596. 2022

Oligoclonal M bands distinguish two MS populations based on neurofilament light chain levels in patients without inflammatory activity

Castillo, J.; (...); Casanova, B.

Meeting Abstract. 2022

Oligoclonal M bands unveil occult inflammation in multiple sclerosis.

Casanova B; (...); Pérez-Miralles F

Article. 10.1016/j.msard.2022.104118. 2022

Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes

Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor

Review. 10.3390/biology12091159. 2023

Online course of pharmacokinetic monitoring in hemophilia with application in the clinical practice

Bonanad, S; (...); Poveda, JL

Meeting Abstract. 2018

Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies.

Coret F; (...); Casanova B

Article. 10.1177/2055217318783347. 2018

OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT

Flores-Moreno, S.; (...); Gil, A.

Meeting Abstract. 2024

Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol

Garcia-Robles, Ana; (...); Carrascosa, MA

Article. 10.3389/fped.2020.00372. 2020

Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Correction. 10.3389/fped.2021.834454. 2022

Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project

Morillo-Verdugo, R; (...); Diaz-Olmo, J

Article. 10.7399/fh.11719. 2021

Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.

Morillo-Verdugo R; (...); Díaz-Olmo J

Article. 2021

Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder

Meca-Lallana, JE; (...); Maurino, J

Article. 10.2147/PPA.S305707. 2021

Perception of stigma in patients with primary progressive multiple sclerosis.

Pérez-Miralles F; (...); Casanova-Estruch B

Article. 10.1177/2055217319852717. 2019

Perception of stigma in people with neuromyelitis optica spectrum disorders (PERSPECTIVES-NMO Study)

Lallana, Jose Meca; (...); Maurino, Jorge

Meeting Abstract. 2021

Peripapillary retinal nerve fibre layer correlates better with spinal cord volume than with brain parenchymal fraction in multiple sclerosis

Barreiro-Gonzalez, A; (...); Casanova, B

Meeting Abstract. 2019

Perturbed glucose metabolism: insights into multiple sclerosis pathogenesis.

Mathur D; (...); Marti MB

Article. 10.3389/fneur.2014.00250. 2014

Pharmaceutical care to hospital outpatients during the COVID-19 pandemic. Telepharmacy

Margusino-Framiñán L; (...); Morillo-Verdugo R

Article. 10.7399/fh.11498. 2020

Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.

Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis

Article. 10.3390/ijms26041760. 2025

Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia

Megias-Vericat, JE; (...); Montesinos, P

Review. 10.2174/1389200218666171101124931. 2018

Pharmacogenomics and the treatment of acute myeloid leukemia

Megías-Vericat JE; (...); Aliño SF

Review. 10.2217/pgs-2016-0055. 2016

Pharmacometabolomics by NMR in Oncology: A Systematic Review.

Gómez-Cebrián N; (...); Pineda-Lucena A

Article. 10.3390/ph14101015. 2021

Pharmacotherapeutic management of advanced therapy medicinal products

Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia

Article. 10.7399/fh.13036. 2022

Pharmacotherapy follow-up of patients under treatment with biologic agents for chronic inflammatory systemic conditions: an agreement among hospital pharmacists for the standardized collection of a minimum set of data.

Calleja Hernández MÁ; (...); Aragon, B

Article. 10.7399/fh.2017.41.1.10463. 2017

Physical Activity In Haemophilia: Hemorrhagic Risk And Factor Levels (myPKFiT)

Querol-Fuentes, F; (...); Bonanad, S

Meeting Abstract. 2017

Pilot evaluation of home delivery programme in haemophilia

Megias-Vericat, JE; (...); Poveda-Andres, JL

Article. 10.1111/jcpt.12718. 2018

PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS

Vericat, JEM; (...); Iorio, A

Meeting Abstract. 2020

Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis

Megías-Vericat JE; (...); Aliño SF

Letter. 10.1038/tpj.2015.79. 2016

Potential Biomarkers Associated with Multiple Sclerosis Pathology.

Mathur, Deepali; (...); Casanova, Bonaventura

Article. 10.3390/ijms221910323. 2021

Potential Role of CHI3L1+ Astrocytes in Progression in MS.

Cubas-Núñez L; (...); Casanova B

Article. 10.1212/NXI.0000000000000972. 2021

Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process

Valero, S; (...); Poveda, JL

Article. 10.1016/j.yrtph.2018.03.001. 2018

Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients.

Tortosa-Carreres J; (...); Pérez-Miralles FC

Article. 10.1016/j.msard.2024.105734. 2024

Predictive value of early brain atrophy on response in patients treated with interferon ß.

Pérez-Miralles FC; (...); Montalban X

Article. 10.1212/NXI.0000000000000132. 2015

Predictive value of isolated CSF NfL and Chi3l1 measures in clinical practice

Gil-Perotin, S; (...); Casanova-Estruch, B

Meeting Abstract. 2018

PRELIMINAR STUDY OF THERAPY ADHERENCE CONTROLLED BY PRESCRIPTION OF MEDICATION AND SELF-PERCEPTION ADHERENCE OF INFLAMMATORY CHRONIC DISEASE PATIENTS

Garcia, EG; (...); Ivorra, JAR

Meeting Abstract. 10.1136/annrheumdis-2019-eular.5937. 2019

Preparación y administración de perfusiones de insulina en neonatología: Encuesta nacional.

García-Robles A; (...); Aguar-Carrascosa M

Letter. 10.1016/j.anpedi.2020.06.008. 2021

Preparation and administration of insulin infusions in neonatology: A national survey.

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Article. 10.1016/j.anpede.2020.06.015. 2021

Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services

Company Albir MJ, Poveda Andrés JL, Edo Solsona MD

Article. 10.1016/j.farma.2023.06.0131130. 2024

Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review

Ballesta-Lopez, Octavio; (...); Luis Poveda-Andres, Jose

Review. 10.7399/fh.11780. 2021

Prognostic Impact of Anthracycline Metabolism Gene Polymorphisms in Newly Diagnosed Acute Myeloid Leukemia Adults

Article. 2014

Prognostic Impact of Cytarabine Pathway Gene Polymorphisms in Acute Myeloid Leukemia Adults Undergoing Induction Chemotherapy

Article. 2014

PROGNOSTIC IMPACT OF TRANSPORTER GENE POLYMORPHISMS IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA ADULTS

Megias Vericat, J. E.; (...); Sanz, M. A.

Article. 2015

Progressive Demyelination in the Presence of Serum Myelin Oligodendrocyte Glycoprotein-IgG: A Case Report

Gil-Perotin, S; (...); Casanova-Estruch, B

Article. 10.3389/fneur.2018.00340. 2018

Prostaglandin Injection After Arterial Compromise Related to Hyaluronic Acid Filler

Letter. 10.1097/DSS.0000000000001046. 2017

Quantification of physical activity in adult patients with haemophilic arthropathy in prophylaxis treatment using a fitness tracker

Perez-Alenda, S; (...); Querol, F

Letter. 10.1111/hae.13388. 2018

Quantifying the patient ' s perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire

Meca-Lallana, JE; (...); Ballesteros, J

Article. 10.1371/journal.pone.0255317. 2021

Quantifying the patient's perspective in neuromyelitis optica spectrum disorders: design of a multicenter, non-interventional study

Meca-Lallana, J; (...); Maurino, J

Meeting Abstract. 2020

Recambio plasmático terapéutico: aplicaciones en neurología.

Láinez-Andrés JM; (...); Santonja JM

Abstract of Published Item. 10.33588/rn.6003.2014393. 2015

Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses.

Ramo-Tello, Cristina; (...); Rovira À

Article. 10.3390/jpm12010006. 2021

Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease

Alcala, C; (...); Casanova, B

Editorial Material. 10.1016/j.msard.2018.12.005. 2019

Reduction in alert fatigue in an assisted electronic prescribing system, through the Lean Six Sigma methodology.

Cuéllar Monreal MJ; (...); Poveda Andrés JL

Article. 10.7399/fh.2017.41.1.10434. 2017

Relapsing inflammatory optic neuropathy: clinical description in a serie of 16 patients

Navarro, L.; (...); Casanova, B.

Meeting Abstract. 2014

Relationship between different cerebrospinal fluid biomarkers in multiple sclerosis: meaning and use in clinical practice

Castillo, J; (...); Casanova, B

Meeting Abstract. 2017

Renal function influences serum neurofilament light chain levels in patients with multiple sclerosis

Gasque Rubio, R.; (...); Casanova Estruch, B.

Meeting Abstract. 2022

Renal function's impact on serum neurofilament levels in patients with multiple sclerosis: an exploratory analysis.

Tortosa-Carreres, Jordi; (...); Perez-Miralles, Francisco

Article. 10.1007/s10072-024-07772-6. 2024

Review of the novelties from the 2014 ECTRIMS-ACTRIMS Joint Congress, presented at the 7th Post-ECTRIMS meeting (I)

Fernandez, Oscar; (...); Tintore, Mar

Article. 10.33588/rn.6105.2015228. 2015

Review of the novelties from the 2014 ECTRIMS-ACTRIMS Joint Congress, presented at the 7th Post-ECTRIMS Meeting (II)

Fernandez O; (...); Grupo Post-Ectrims GP

Article. 10.33588/rn.6106.2015239. 2015

Review of the novelties from the 32nd ECTRIMS Congress, 2016, presented at the 9th Post-ECTRIMS Meeting (I)

Fernandez, O; (...); Rodriguez-Antiguedad, A

Review. 10.33588/rn.6501.2017168. 2017

Review of the novelties from the 32nd ECTRIMS Congress, 2016, presented at the 9th Post-ECTRIMS Meeting (II)

Fernandez, Oscar; (...); Rodriguez-Antiguedad, Alfredo

Review. 10.33588/rn.6502.2017169. 2017

Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I).

Fernández Ó; (...); Grupo Post-ECTRIMS

Article. 10.33588/rn.5705.2013270. 2013

Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).

Fernandez O; (...); Grupo Post-Ectrims GP

Article. 10.33588/rn.5706.2013276. 2013

Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III).

Fernández Ó; (...); Post-ECTRIMS Group

Article. 10.33588/rn.5707.2013277. 2013

Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I)

Fernandez O; (...); Grupo Post-Ectrims GP

Article. 10.33588/rn.5906.2014321. 2014

Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II)

Fernandez, Oscar; (...); Rodriguez-Antigueedad, Alfredo

Article. 10.33588/rn.5907.2014334. 2014

Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III)

Fernández Ó; (...); Grupo Post-ECTRIMS

Article. 10.33588/rn.5908.2014335. 2014

Revision de las novedades del congreso conjunto ECTRIMS-ACTRIMS 2014, presentadas en la VII Reunion Post-ECTRIMS (I).

Fernandez O; (...); Grupo Post-Ectrims GP

Abstract of Published Item. 10.33588/rn.6105.2015228. 2015

Revision de las novedades del XXXII Congreso ECTRIMS 2016, presentadas en la IX Reunion Post-ECTRIMS (II).

Fernandez O; (...); Rodriguez-Antiguedad A

Article. 10.33588/rn.6502.2017169. 2017

Risk of transition to secondary progressive multiple sclerosis and accumulation of disability in progressive multiple sclerosis are not influenced by current therapies

Alcala, C; (...); Casanova, B

Meeting Abstract. 2017

Safety profile and practical considerations of monoclonal antibody treatment.

Casanova Estruch B

Article. 10.1016/j.nrl.2011.02.004. 2013

Salvage therapy with topical posaconazole in lung transplant recipients with invasive Scedosporium infection.

Sole, A; (...); Peman, J

Article. 10.1111/ajt.14580. 2018

SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry.

Arrambide, Georgina; (...); Meca-Lallana, Jose E

Article. 10.1212/NXI.0000000000001024. 2021

SEFH National Survey-2019: general characteristics, staffing, material resources and information systems in Spain's hospital pharmacy departments.

Pérez-Encinas M; (...); Calleja-Hernández MÁ

Article. 10.7399/fh.11565. 2020

Selective ophthalmic intra-arterial melphalan therapy for advanced retinoblastoma: implementation and outcomes of a new chemotherapy protocol.

Valero García S; (...); Poveda Andrés JL

Article. 10.1177/1078155212457964. 2013

Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice

Aguas Peris M; (...); Nos, P

Article. 10.1097/MIB.0000000000001182. 2017

Serum adalimumab levels predict successful remission and safe de-intensification in inflammatory bowel disease patients in clinical practice

Aguas, M; (...); Nos, P

Meeting Abstract. 2017

Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.

Fissolo, Nicolas; (...); Comabella, Manuel

Article. 10.1136/jnnp-2023-332251. 2023

Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.

Monreal E; (...); Villar LM

Article. 10.1093/brain/awae260. 2024

Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels at Disease Onset for Prediction of the Risk of Disability Worsening in Patients with Multiple Sclerosis

Monreal, Enric; (...); Villar Guimerans, Luisa Maria

Meeting Abstract. 2023

Serum neurofilament light chain and glial fibrillary acidic protein levels at disease onset unveil immunological pathways of disability acquisition in multiple sclerosis

Monreal, Enric; (...); Villar Guimerans, Luisa Maria

Meeting Abstract. 2024

Serum Neurofilament Light Chain is a surrogate marker of NEDA-3 in Multiple Sclerosis

Gascon Gimenez, Francisco Guillermo; (...); Casanova, Bonaventura

Meeting Abstract. 2023

Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study).

Pérez-Miralles F; (...); Casanova B

Article. 10.1016/j.msard.2021.102860. 2021

Silent Progression or Bout Onset Progressive Multiple Sclerosis?

Gil-Perotin, S; (...); Casanova, B

Letter. 10.1002/ana.25537. 2019

Single Nucleotide Polymorphisms, SNPs, Associated With the Efficacy and Security of Immunosuppressive Treatment in Heart Transplantation

Sanchez-Lazaro, I.; (...); Salvador-Sanz, A.

Article. 10.1016/j.healun.2014.01.392. 2014

SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization

Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis

Article. 10.1111/jcpt.13703. 2022

SNPs and taxane toxicity in breast cancer patients

Bosó V; (...); Aliño SF

Article. 10.2217/PGS.14.127. 2014

Somatic hypermutation of intrathecal IgM-producing B cells in multiple sclerosis patients

Beltran, Eduardo; (...); Casanova, Bonaventura

Article. 2012

Spanish Consensus on the Prevention and Treatment of Pseudomonas aeruginosa Bronchial Infections in Cystic Fibrosis Patients

Cantón R; (...); Solé A

Article. 10.1016/j.arbres.2014.09.021. 2015

Spanish registry of multiple sclerosis patients on glatiramer acetate 40 mg/ml treatment: Real-world results and baseline characteristics of initial patients

Fernandez, O; (...); Sanchez-de la Rosa, R

Meeting Abstract. 2017

Spanish Registry of patients with multiple sclerosis treated with fingolimod (GILENYA Registry): safety and effectiveness after one year on treatment

Rodriguez-Antigueedad, A.; (...); Fernandez, O.

Article. 2014

Spinal cord atrophy but not brain atrophy measures, correlates with the Multiple Sclerosis Severity Score

Carratala, S; (...); Estruch, BC

Meeting Abstract. 2018

Study on the Linezolid Prescription According to the Approval of Indication in a University Hospital

Pérez-Cebrián M; (...); Llopis-González A

Article. 2015

Sustained hyperammonemia induces TNF-a IN Purkinje neurons by activating the TNFR1-NF-?B pathway.

Balzano T; (...); Felipo V

Article. 10.1186/s12974-020-01746-z. 2020

Symptom severity in Neuromyelitis Optica Spectrum Disorder from the patients' perspective

Meca-Lallana, J.; (...); Maurino, J.

Meeting Abstract. 2021

Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia

Megías-Vericat JE; (...); Montesinos P

Review. 10.3390/pharmaceutics14040878. 2022

The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity

Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar

Article. 10.1007/s00431-022-04628-z. 2022

The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.

Gil-Nagel A; (...); Gil A

Article. 10.1016/j.yebeh.2022.108711. 2022

The effect of intravenous immunoglobulin on neuromyelitis optica.

Magraner MJ, Coret F, Casanova B

Article. 10.1016/j.nrl.2012.03.014. 2013

The impact of stigma in people with primary progressive multiple sclerosis

Perez-Miralles, F; (...); Casanova-Estruch, B

Meeting Abstract. 2018

The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).

Badia, Xavier; (...); Valles, Joan-Antoni

Article. 10.1186/s13023-024-03324-5. 2024

The view of experts on initiatives to be undertaken to promote equity in the access to orphan drugs and specialised care for rare diseases in Spain: A Delphi consensus

Torrent-Farnell, J; (...); Lizan, L

Article. 10.1016/j.healthpol.2018.03.002. 2018

Therapeutic plasma exchange: applications in neurology

Lainez-Andres, Jose M.; (...); Santonja, Jose M.

Article. 10.33588/rn.6003.2014393. 2015

Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule.

Marques MR; (...); Mangas-Sanjuan V

Article. 10.1111/apa.14944. 2020

Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy

Del Rio-Bermudez, C; (...); Poveda, JL

Editorial Material. 10.1186/s40545-020-00276-6. 2020

Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.

Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis

Article. 10.1136/ejhpharm-2024-004184. 2024

Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs.

Megías Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.rx.2015.01.008. 2015

Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature

Lizan, L; (...); Polanco, C

Review. 10.2147/PPA.S67253. 2014

Treatment of multiple sclerosis with Rituximab: a multicenter Spanish experience